The treatment of rejection. A trial of acetylsalicylic acid, dipyridamole, and heparin.
Serial studies of platelet and fibrinogen survival were performed in 26 nonimmunosuppressed dogs after allogenic renal transplant operations. Treatment with acetylsalicylic acid, dipyridamole, and heparin failed to improve the selective platelet destruction which occurred in untreated animals, and it did not improve postoperative longevity. There was a high incidence of postoperative wound and intrarenal hemorrhage after heparin treatment. These results are consistent with the hypothesis that platelet destruction is a consequence rather than the cause of acute graft rejection, and it is concluded that antithrombotic therapy is not of practical benefit in preventing acute rejection.
D000818:Animals; D001241:Aspirin / Q000627:therapeutic use*; D001792:Blood Platelets; D002470:Cell Survival; D004176:Dipyridamole / Q000627:therapeutic use*; D004285:Dogs; D005340:Fibrinogen / Q000032:analysis; D006084:Graft Rejection / Q000188:drug therapy*; D006493:Heparin / Q000627:therapeutic use*; D007668:Kidney / Q000473:pathology; D016030:Kidney Transplantation; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
D004176:Dipyridamole; D005340:Fibrinogen; D006493:Heparin; D001241:Aspirin